Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis.

ABSTRACT:

Background

Novel immunotherapeutic strategies targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis are often administered when metastatic tumors show PD-L1 positivity, even in the setting of lung cancer brain metastasis (LCBM). However, biological differences exist between primary tumors and metastatic sites. The objective of this study was to analyze rates of PD-L1 receptor discordance between primary tumors and LCBM.

Methods

A systematic review of studies of biopsied or resected LCBM evaluating PD-L1 discordance published in the Medline database was performed using PRISMA guidelines. Weighted random effects models were used to calculate pooled estimates.

Results

Six full-text articles (n = 230 patients) with a median of

SUBMITTER: Tonse R 

PROVIDER: S-EPMC8704382 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature